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Six different Treponema (TP)-specific immunoassays were compared to the fluorescent treponemal antibody absorption (FTA-
ABS) test. A total of 615 samples were tested. The overall percent agreement, analytical sensitivity, and analytical specificity of
each assay compared to the FTA-ABS test were as follows: Architect Syphilis TP, 99.2%, 96.8%, and 100%; Cobas Syphilis, 99.8%,
99.4%, and 100%; ADVIA Centaur Syphilis, 99.8%, 99.4%, and 100%; HISCL Anti-TP assay kit, 99.7%, 98.7%, and 100%; Immu-
noticles Auto3 TP, 99.0%, 97.5%, and 99.6%; Mediace TPLA, 98.0%, 98.1%, and 98.0%. All results that were discrepant between
the TP-specific assays were associated with samples from noninfectious cases (11 immunoassay false positives and 7 from previ-
ous syphilis cases). Our study demonstrated that TP-specific immunoassays generally showed high sensitivities, specificities, and
percentages of agreement compared to FTA-ABS, with rare cases of false-positive or false-negative results. Therefore, most TP-
specific immunoassays are acceptable for use in screening for syphilis. However, it is important to perform a thorough review of
a patient’s clinical and treatment history for interpreting the results of syphilis serology.
Syphilis is commonly diagnosed on the basis of the results of acombination of serological tests to detect Treponema (TP) an-
tibodies and non-TP antibodies (1). A traditional screening algo-
rithm for syphilis that began with a non-TP assay failed to detect
3% of syphilis cases, in a previous study (2). Recently, a reverse-
screening algorithmwith an automated TP-specific assay has been
recommended by the European Centers for Disease Control and
Prevention (ECDC) (3). CDC continues to recommend the tradi-
tional algorithm and yet also recognizes the recent trend of the
widespread use of the reverse algorithm and recommends extra
TP tests to resolve discordant results (4). The reverse algorithm
has been found to show superior diagnostic performance, with
sensitivities ranging from 99.38% to 99.85%, specificities from
99.98% to 100%, and accuracies from 99.93% to 99.96% com-
pared with a 24.2% missed-diagnosis rate and 75.81% sensitivity
of the traditional algorithm (5).
Various automated TP-specific immunoassays have been de-
veloped that use either whole cells or antigens, such as 15TpN,
17TpN, and 47TpN, derived from theNichols strain ofTreponema
pallidum, to detect IgG, IgM, or total immunoglobulins (1). Ini-
tially, enzyme immunoassays (EIAs) were commonly used to de-
tect TP-specific antibodies (5, 6). However, the use of chemilumi-
nescence immunoassays (CLIAs) to detect TP-specific IgG and
IgM antibodies has been gradually increasing (6, 7). Additionally,
quantitative TP-specific immunoassays using turbidimetry, based
on a latex agglutination method, have been widely used in Asia.
However, comparative analyses of the performances of these var-
ious methods are lacking.
The aim of this study was to evaluate the performances of 6
commonly used TP-specific immunoassays, including CLIAs and
turbidimetry assays, in comparison with the performance of the
fluorescent treponemal antibody absorption (FTA-ABS) test.
MATERIALS AND METHODS
Study design. A total of 615 samples were tested using the 6 kinds of
automated TP-specific immunoassays. These samples included 613 left-
over serum samples that had been sent for TP or non-TP assay and 2
international standards for syphilis (no. 05/122 and 50/132; National In-
stitute for Biological Standards and Control [NIBSC], Hertfordshire,
United Kingdom). The samples included those from 105 medical check-
ups of healthy individuals, 179 preoperative evaluations of patients with
variable underlying disease, and 329 suspected cases of current or previ-
ous syphilis. The median age of all patients was 48 years (range, 5 to 93
years). All immunoassay results were compared with those of the FTA-
ABS test (Zeus Scientific, NJ, USA). In addition, the Venereal Disease
Research Laboratory (VDRL) test was performed and clinical history was
reviewed for samples with discordant TP-specific assay results. Samples
were stored at 4°C until all testing was complete. The study protocol was
reviewed by the institutional review board at our hospital.
Treponema-specific immunoassays. All six kinds of TP-specific im-
munoassays were performed following the manufacturer’s instructions.
Assays evaluated included Architect Syphilis TP (Abbott Diagnostics, To-
kyo, Japan), Cobas Syphilis (Roche Diagnostics, Mannheim, Germany),
ADVIA Centaur Syphilis (Siemens Healthcare Diagnostics, NY, USA),
HISCL Anti-TP assay kit (Sysmex Corporation, Kobe, Japan), Immu-
noticles Auto3 TP (A & T Corporation, Kanagawa, Japan), and Mediace
TPLA (Sekisui Medical Co, Tokyo, Japan). Two of these assays are quan-
titative assays: Immunoticles Auto3 TP and Mediace TPLA. Characteris-
tics of the 6 different immunoassays are presented in Table 1.
FTA-ABS and VDRL tests. The FTA-ABS assay, which uses the non-
viable Nichols strain of T. pallidum for detection of TP-specific total an-
tibodies, was performed according to the manufacturer’s instructions.
Every batch of patient samples was tested with negative and positive con-
trols, and the results of positive samples were graded on a scale from1
to4.
The quantitative VDRL test was performed using a BDVDRLAntigen
kit (Becton, Dickinson and Company, MD, USA) according to the man-
ufacturer’s instructions. Serum samples were quantitated to an endpoint
titer of 1:32.
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All FTA-ABS and VDRL tests were reviewed by 2 clinical pathologists
in the laboratory.
Neutralization assay using TP-specific antigen.Neutralization assay
reagents were additionally provided for two quantitative immunoturbi-
dimetric assays: Immunoticles Auto3 TP andMediace TPLA. Purified TP
antigens provided by each vendor were mixed with patient samples and
incubated for 30 min at room temperature. Raw samples and neutralized
samples were tested at the same time. If the TP antibody titer was consid-
erably lower than the value determined before neutralization, the sample
was considered a true positive for TP-specific antibodies.
Statistical analysis. Statistical analyses were performed using Med-
Calc Statistical Software version 15.6.1 (MedCalc Software bvba, Ostend,
Belgium). We evaluated 6 TP assays for analytical sensitivity and specific-
ity and for percent agreement by kappa () coefficients. Linear regression
analysis was used to compare quantitative results, and the Kruskal-Wallis
test was used to compare results among different groups. The Mann-
WhitneyU test was used to evaluate differences between 2 groups.P values
of0.01 were considered statistically significant.
RESULTS
Results of automated immunoassays. A total of 157 samples
from 155 patients (median age, 56 years; range, 19 to 93 years) and
2 standards showed positive results. The overall percentages of
agreement and corresponding values of each assay’s results com-
pared with those of FTA-ABS were as follows: for Architect Syph-
ilis TP, 99.2%, 0.978; forCobas Syphilis, 99.8%, 0.996; for
ADVIA Centaur Syphilis, 99.8%,   0.996; for the HISCL An-
ti-TP assay kit, 99.7%,   0.991; for Immunoticles Auto3 TP,
99.0%,   0.974; and for Mediace TPLA, 98.0%,   0.949 (Ta-
ble 2). The analytical sensitivities of the assays were 96.8%, 99.4%,
99.4%, 98.7%, 97.5%, and 98.1%, and the specificities were 100%,
100%, 100%, 100%, 99.6%, and 98.0%, respectively. Eighteen
samples that showed results that were discrepant between the TP-
specific assays were from noninfectious cases. Seven of these re-
sults were from cases confirmed by clinical history to represent
previous syphilis cases, and 11 of these results (2 from healthy
individuals, 1 from a 90-year-old allergic dermatitis patient with-
out a history of syphilis, and 8 frompatientswith variousmalignan-
cies who were tested to evaluate preoperative condition without in-
fectious symptoms) were considered to represent false-positive
reactions of the immunoassay (Table 3).
Neutralization assay using TP-specific antigen in a quantita-
tive turbidimetry assay. The 11 false-positive, nonspecific reac-
tions were found only in the turbidimetry immunoassays, i.e.,
Immunoticles Auto3 TP and the Mediace TPLA assay (Table 3).
Nine of these results were from the Mediace TPLA. All 11 results
were confirmed to be false positives by neutralization assay. Ten
true-positive sera, diluted to various concentrations, were tested
in parallel using the neutralization assay as a control; none of the
results from these samples were identified as false positives.
Analyses of the quantitative assays. The linear analytic mea-
surable range (AMR) for the Immunoticles Auto3 TP assay was 0
to 300U/ml and for theMediace TPLAwas 0 to 250U/ml, accord-
ing to the manufacturer’s instructions. A total of 531 data points
were within the linear AMR. The 2 quantitative assays showed
good correlation by linear regression analysis within the linear
AMR (y 1.3674 1.7779, R2 0.8805, P 0.0001) (Fig. 1).
All data points over the AMR were obtained after dilution, and 9
outliers were excluded. Outliers were defined as those points that
were over 1,000 units in Immunoticles Auto3 TP but less than 250
titer units (TU) inMediace TPLA. The regression analysis of theseT
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606 data points showed better correlation (y  1.4243 
15.6419, R2 0.9679, P 0.0001) than the analysis with the full
range of data (Fig. 1).
In addition, quantitative results from immunoassays were as-
sociated with graded results of the FTA-ABS assay (Fig. 2). Quan-
titative assays showed false-positive results, but these assays could
differentiate between high-grade positivity (score of 3 or 4)
and low-grade positivity (1 or 2). However, there were no
statistically significant differences between results with scores of
3 and 4 or between those with scores of 1 and 2 in the
Immunoticles Auto3 TP and Mediace TPLA assays (Fig. 2). The
units of the 2 biological standards were 0.3 IU/ampoule (for stan-
dard 05/122) and 3 IU/ampoule (for standard 05/132). Theymea-
sured 455 and 3,400TUbyMediace TPLA and 260 and 1,610 units
by Immunoticles Auto3 TP assays.
DISCUSSION
Our findings indicated that commercial TP-specific immunoas-
says currently in use show high sensitivities, specificities, and per-
centages of agreement compared with FTA-ABS. However, rare
cases of false positives or false negatives resulted. False-positive
reactions in both non-TP-specific and TP-specific assays aremore
likely to be seen under specific conditions, such as viral or bacterial
infection, autoimmune disease, pregnancy, postimmunization
status, diabetes, and old age (1, 6). Therefore, without a known
history of syphilis or a positive anti-TP IgM test result, persistent
TABLE 2 Evaluation of various Treponema assays in comparison with the FTA-ABSa assay
Assay and result
No. of FTA-ABS test results
% sensitivity % specificity % agreement Kappa value (range) [SE]Reactive Nonreactive
Abbott
Architect
Reactive 152 0 96.8 100.0 99.2 0.978 (0.960–0.997) [0.010]
Nonreactive 5 458
Roche Cobas
Reactive 156 0 99.4 100.0 99.8 0.996 (0.987–1.000) [0.004]
Nonreactive 1 458
ADVIA Centaur
Reactive 156 0 99.4 100.0 99.8 0.996 (0.987–1.000) [0.004]
Nonreactive 1 458
Sysmex HISCL
Reactive 155 0 98.7 100.0 99.7 0.991 (0.980–1.000) [0.006]
Nonreactive 2 458
A&T
Immunoticles
Reactive 153 2 97.5 99.6 99.0 0.974 (0.954–0.998) [0.010]
Nonreactive 4 456
Sekisui Mediace
Reactive 154 9 98.1 98.0 98.0 0.949 (0.921–0.978) [0.014]
Nonreactive 3 449
a FTA-ABS, fluorescent treponemal antibody absorption.
TABLE 3 Data on 18 results that were discordant between Treponema-specific immunoassays of 615 specimens
Result type(n)a Total no. of results
Test reactivityb
VDRL
(titer) FTA-ABS (score) Abbott Roche Siemens Sysmex A&T Co. Sekisui
False positive (11) 7 R
2 R
2 R (1:1) R
False negative (7) 1 R (1)
1 R (3) R R R R R
1 R (2) R R R
2 R (1:1) R (2) R R R R R
1 R (1:1) R (2) R R R R R
1 R (1:1) R (1) R R R
a False-positive or false-negative results in any of the Treponema-specific immunoassays were confirmed by neutralization assay and clinical history of patients.
b VDRL, Venereal Disease Research Laboratory; FTA-ABS, fluorescent treponemal antibody absorption; R, reactive.
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or transient reactivity in a non-TP or TP assay should be consid-
ered a false-positive reaction. In our study, false-positive results
were seen only with turbidimetric immunoassays, especially Me-
diace TPLA. Previously, 1.2% false positives were reported for a
latex-agglutinated assay used on samples from non-syphilis pa-
tients (8). The neutralization assay was employed to rule out false-
positive reactions, and it effectively distinguished between true
and false-positive reactions. Therefore, neutralization assay con-
firmation should be considered, especially with results ofMediace
TPLA testing.
Additionally, false-positive results can be ruled out by algo-
rithm. If positive TP results with negative non-TP results are ob-
served in a patient without a history of treatment, a second TP-
specific test can be performed to rule out early or late/latent
disease (4, 9).
False-negative non-TP tests can result from the prozone phe-
nomenon in early, secondary, or latent syphilis. This phenome-
non has rarely been observed to affect TP-specific assays (1, 6). In
addition, insufficient antibody production, usually in the 2 to 4
weeks after infection, might lead to false-negative results in TP-
specific immunoassays. False-positive results are rare in active
syphilis cases because most immunoassays currently in use can
detect both the IgM and IgG subtypes of TP-specific antibodies.
According to our data, all 7 false-negative results were from pre-
vious or treated syphilis cases.
In this study, results that were discordant between the various
TP-specific immunoassays were observed. Regardless of which al-
gorithm is used andbecause of the analytical limitations of syphilis
immunoassays, it is important for the clinician always to take the
clinical history of a patient into consideration.
Several commercial, quantitative TP assays have been intro-
duced, and our study showed good correlation between the 2
quantitative turbidimetric assays. In addition, quantitative results
FIG 1 Linear regression of two quantitative Treponema-specific immunoas-
says. (A) A total of 531 data points within the linear analytical measurable
range (AMR) of each assay (300 units for Immunoticles and 250 titer units for
Mediace). (B) A total of 606 data points obtained after dilution of samples,
showing the data over the AMR and excluding 9 data points as outliers.
FIG 2 Comparison between the quantitative results of Treponema-specific
immunoassays and grades of the FTA-ABS (fluorescent treponemal antibody
absorption) test. (A) Comparison between Mediace TPLA and FTA-ABS re-
sults. (B) Comparison between Immunoticles Auto3 TP and FTA-ABS results.
All P values were determined by Mann-Whitney U tests.
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correlated with low and high titer results from FTA-ABS testing.
However, the quantitative results from testing of the biological
standards from NIBSC (provided in 2014) did not match to the
unit value of each material in our study. In our study, Mediace
TPLA and Immunoticles Auto3 TP measured NIBSC standard
material values of 0.3 IU for Treponema-specific IgG and IgM and
measured 3 IU of syphilis antibody as 455 TU and 260 units and as
3,400 TU and1,610 units, respectively. Thus, the unit values of the
TPLA results for standards should be reevaluated.
Previous reports have shown that quantitative results of syph-
ilis assays differed according to the clinical cases and that TP an-
tibody values over 1,000 U were helpful to determine syphilis in-
fection (8). However, the linear AMR values of quantitative assays
are under 300 U. Therefore, sufficient dilutions may be necessary
in quantitative assays to differentiate infectious from non-infec-
tious (previous) syphilis cases.
Although hands-on times did not differ between assays, the
analytical assay times were shorter in quantitative turbidimetric
assays than in qualitative immunoassays (Table 1). Additionally,
the costs of turbidimetric assays ($1 to $2) were lower than those
of immunoassays ($3 to $5). However, the quantitative turbidi-
metric assays required a longer analytical time for positive samples
and were relatively expensive in areas with a high prevalence of
syphilis due to the need to include a dilution process of samples to
showwhich data points were above the AMR. Therefore, the prev-
alence of syphilis must be considered in order to determine the
kind of TP-specific assay to be used in laboratory.
In recent years, automated assays to detect TP antibodies and
reverse algorithm to detect clinical syphilis have been frequently
used (10). However, overtreatment following false-positive test
results is known to occur. On the other hand, the sensitive detec-
tion of TP-specific antibody provides an advantage in areas of low
syphilis prevalence (7).
In our study, various TP-specific immunoassays performed
well in comparison with the FTA-ABS test. Therefore, these TP-
specific immunoassays are sufficient to screen for syphilis. How-
ever, it is important to performa thorough reviewof each patient’s
clinical and treatment history in interpreting the results of syphilis
serology because of their analytical limitations.
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